Novo Nordisk prepares to launch diabetes tablet in India

Rybelsus may be accessible for diabetes patients in India from 2022 onwards, states Novo Nordisk.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk has set its sights on India's large group of diabetes patients as a future market for the treatment Rybelsus, which is the tablet-based form of the Danish pharmaceutical company's newest diabetes treatment semaglutide.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading